Skip to content
Tenfell
Awarded contract
Published 20 Mar 2020

NHS Framework for the NHS North of England Region, Branded Medicines – Tranche B, Cytokine Modulatorsand other Monoclonal Antibodies, and Fondaparinux

The NHS Commissioning Board (operating under the name of NHS England) · United Kingdom

Key facts

Awarded
13 Feb 2020
Contract starts
01 Mar 2020
Contract ends
28 Feb 2022
Procedure
Open procedure (framework)
Buyer type
Health

Awarded to 35 suppliers

SupplierValue
Takeda UK Limited—
Aventis Pharma Ltd Trading As Sanofi—
Dr Reddy's Laboratories (UK) Ltd—
Pfizer Ltd—
Teva UK Ltd—
Bayer plc—
Typharm Ltd—
Biogen—
Eli Lilly & Company Ltd—
Gedeon Richter UK Ltd—
Gilead Sciences Limited—
Ipsen—
Novartis Pharmaceuticals UK Ltd—
Novo Nordisk—
Ferring Pharmaceuticals Limited—
LEO Pharma Ltd—
Bristol-Myers Squibb Pharmaceuticals Ltd—
ROVI Biotech Ltd—
Astellas Pharma Ltd—
Pharmasure—
Theramex HQ UK—
Daiichi Sankyo UK Ltd—
Profile Pharma Ltd—
Aspen Pharma Ireland Ltd—
Merck—
Acre Pharma Limited—
Generics [UK] ta Mylan—
Janssen-Cilag Ltd—
MSD—
Amgen Ltd—
Napp Pharmaceuticals—
Sandoz Ltd—
Celltrion Healthcare United Kingdom Limited—
Roche Products Ltd—
UCB Pharma Ltd—

Categories (CPV)

Similar open tenders

About The NHS Commissioning Board (operating under the name of NHS England)

Their tenders, awards, contracts coming up for renewal, decision makers and committee papers.

View buyer profile

Published by the buyer on TED archive (UK notices before Brexit) (EU open data (Decision 2011/833/EU)). Always read the original notice before responding.